Experimental confirmation of new drug-target interactions predicted by drug profile matching

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8377-8388

  Végner, László ^a   Peragovics, Ágnes ^a   Tombor, László ^b   Jelinek, Balázs ^a,c   Czobor, Pál ^b   Bender, Andreas ^d   Simon, Zoltán ^a,c,e   Málnási Csizmadia, András ^a,c  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Drugmotif Ltd   (Hungary)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Delta Informatika Inc   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CANDOXATRIL; CAPTOPRIL; CARVEDILOL; CELECOXIB; CICLOPIROX; CYCLOOXYGENASE 2 INHIBITOR; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUTAMIDE; LINOLENIC ACID; NEBIVOLOL; NELFINAVIR; NILUTAMIDE; NITROFURAL; NITROXOLINE; NONSTEROID ANTIINFLAMMATORY AGENT; NOVOBIOCIN; OXYBENZONE; PROLINE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; TELMISARTAN; TICLOPIDINE; TIPRANAVIR; UNINDEXED DRUG; VALDECOXIB; VALPROIC ACID;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CELL CULTURE; DOPAMINERGIC ACTIVITY; DRUG REPOSITIONING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; LIGAND BINDING; OXIDATION; THROMBOSIS;

ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CHO CELLS; CRICETULUS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR CONFORMATION; MOLECULAR TARGETED THERAPY; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84887978605     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400813y     Document Type: Article

References (92)

1. Kling, J. Fresh from the biotech pipeline-2011 [corrected] Nat. Biotechnol. 2012, 30, 128-131
2. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discovery 2004, 3, 673-683
3. Jabbour, E.; Kantarjian, H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management Am. J. Hematol. 2012, 87, 1037-1045
4. Eisenberg, B. L.; Pipas, J. M. Gastrointestinal stromal tumor-background, pathology, treatment Hematol Oncol Clin North Am. 2012, 26, 1239-1259
5. Ekman, P. Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy Scand. J. Urol. Nephrol., Suppl. 1999, 203, 15-20
6. Cleach, L. L.; Bocquet, H.; Roujeau, J. C. Reactions and interactions of some commonly used systemic drugs in dermatology Dermatol. Clin. 1998, 16, 421-429
7. Patrono, C.; Garcia Rodriguez, L. A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the prevention of atherothrombosis N. Engl. J. Med. 2005, 353, 2373-2383
8. Patrono, C.; Rocca, B. Aspirin, 110 years later J. Thromb. Haemostasis 2009, 7 (Suppl. 1) 258-261
9. Krejsa, C. M.; Horvath, D.; Rogalski, S. L.; Penzotti, J. E.; Mao, B.; Barbosa, F.; Migeon, J. C. Predicting ADME properties and side effects: the BioPrint approach Curr. Opin. Drug Discoveru Dev. 2003, 6, 470-480
10. Fliri, A. F.; Loging, W. T.; Thadeio, P. F.; Volkmann, R. A. Analysis of drug-induced effect patterns to link structure and side effects of medicines Nat. Chem. Biol. 2005, 1, 389-397
11. Fliri, A. F.; Loging, W. T.; Thadeio, P. F.; Volkmann, R. A. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response J. Med. Chem. 2005, 48, 6918-6925
12. Fliri, A. F.; Loging, W. T.; Thadeio, P. F.; Volkmann, R. A. Biological spectra analysis: linking biological activity profiles to molecular structure Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 261-266
13. Kauvar, L. M.; Higgins, D. L.; Villar, H. O.; Sportsman, J. R.; Engqvist-Goldstein, A.; Bukar, R.; Bauer, K. E.; Dilley, H.; Rocke, D. M. Predicting ligand binding to proteins by affinity fingerprinting Chem. Biol. 1995, 2, 107-118
14. Hsu, N.; Cai, D.; Damodaran, K.; Gomez, R. F.; Keck, J. G.; Laborde, E.; Lum, R. T.; Macke, T. J.; Martin, G.; Schow, S. R.; Simon, R. J.; Villar, H. O.; Wick, M. M.; Beroza, P. Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints J. Med. Chem. 2004, 47, 4875-4880
15. Koutsoukas, A.; Simms, B.; Kirchmair, J.; Bond, P. J.; Whitmore, A. V.; Zimmer, S.; Young, M. P.; Jenkins, J. L.; Glick, M.; Glen, R. C.; Bender, A. From in silico target prediction to multi-target drug design: current databases, methods and applications J. Proteomics 2011, 74, 2554-2574
16. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136
17. Mestres, J.; Gregori-Puigjane, E.; Valverde, S.; Sole, R. V. The topology of drug-target interaction networks: implicit dependence on drug properties and target families Mol BioSyst. 2009, 5, 1051-1057
18. Paolini, G. V.; Shapland, R. H.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space Nat. Biotechnol. 2006, 24, 805-815
19. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands Drug Discovery Today 2007, 12, 156-160
20. Mestres, J.; Gregori-Puigjane, E.; Valverde, S.; Sole, R. V. Data completeness-the Achilles heel of drug-target networks Nat. Biotechnol. 2008, 26, 983-984
21. Lagunin, A.; Stepanchikova, A.; Filimonov, D.; Poroikov, V. PASS: prediction of activity spectra for biologically active substances Bioinformatics 2000, 16, 747-748
22. Bender, A.; Jenkins, J. L.; Glick, M.; Deng, Z.; Nettles, J. H.; Davies, J. W. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: When are multitarget drugs a feasible concept? J. Chem. Inf. Model. 2006, 46, 2445-2456
23. Bender, A.; Scheiber, J.; Glick, M.; Davies, J. W.; Azzaoui, K.; Hamon, J.; Urban, L.; Whitebread, S.; Jenkins, J. L. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure ChemMedChem 2007, 2, 861-873
24. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry Nat. Biotechnol. 2007, 25, 197-206
25. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs Nature 2009, 462, 175-181
26. Simon, Z.; Peragovics, A.; Vigh-Smeller, M.; Csukly, G.; Tombor, L.; Yang, Z.; Zahoranszky-Kohalmi, G.; Vegner, L.; Jelinek, B.; Hari, P.; Hetenyi, C.; Bitter, I.; Czobor, P.; Malnasi-Csizmadia, A. Drug effect prediction by polypharmacology-based interaction profiling J. Chem. Inf. Model. 2012, 52, 134-145
27. Peragovics, A.; Simon, Z.; Brandhuber, I.; Jelinek, B.; Hari, P.; Hetenyi, C.; Czobor, P.; Malnasi-Csizmadia, A. Contribution of 2D and 3D structural features of drug molecules in the prediction of drug profile matching J. Chem. Inf. Model. 2012, 52, 1733-1744
28. Ferreira, S. H. Angiotensin converting enzyme: history and relevance Semin. Perinatol. 2000, 24, 7-10
29. Hackam, D. G.; Khan, N. A.; Hemmelgarn, B. R.; Rabkin, S. W.; Touyz, R. M.; Campbell, N. R.; Padwal, R.; Campbell, T. S.; Lindsay, M. P.; Hill, M. D.; Quinn, R. R.; Mahon, J. L.; Herman, R. J.; Schiffrin, E. L.; Ruzicka, M.; Larochelle, P.; Feldman, R. D.; Lebel, M.; Poirier, L.; Arnold, J. M.; Moe, G. W.; Howlett, J. G.; Trudeau, L.; Bacon, S. L.; Petrella, R. J.; Milot, A.; Stone, J. A.; Drouin, D.; Boulanger, J. M.; Sharma, M.; Hamet, P.; Fodor, G.; Dresser, G. K.; Carruthers, S. G.; Pylypchuk, G.; Burgess, E. D.; Burns, K. D.; Vallee, M.; Prasad, G. V.; Gilbert, R. E.; Leiter, L. A.; Jones, C.; Ogilvie, R. I.; Woo, V.; McFarlane, P. A.; Hegele, R. A.; Tobe, S. W. The 2010 Canadian hypertension education program recommendations for the management of hypertension: part 2-therapy Can J Cardiol. 2010, 26, 249-258
30. DrugBank, Open Data Drug & Drug Target Database: Candoxatril. http://www.drugbank.ca/drugs/DB00616.
31. Cohen Solal, A.; Jondeau, G.; Beauvais, F.; Berdeaux, A. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure Eur. J. Heart Failure 2004, 6, 463-466
32. Flordellis, C. S.; Goumenos, D.; Kourounis, G.; Tsementzis, S. A.; Paris, H.; Vlachojiannis, J. The shift in the "paradigm" of the pharmacology of hypertension Curr. Top. Med. Chem. 2004, 4, 487-498
33. Margulies, K. B.; Perrella, M. A.; McKinley, L. J.; Burnett, J. C., Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure J. Clin. Invest. 1991, 88, 1636-1642
34. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening J. Med. Chem. 2002, 45, 1712-1722
35. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs J. Med. Chem. 2003, 46, 4477-4486
36. Yusuf, S.; Teo, K.; Anderson, C.; Pogue, J.; Dyal, L.; Copland, I.; Schumacher, H.; Dagenais, G.; Sleight, P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 2008, 372, 1174-1183
37. Eder, J. P.; Wheeler, C. A.; Teicher, B. A.; Schnipper, L. E. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity Cancer Res. 1991, 51, 510-513
38. Takahashi, N.; Miura, M.; Scott, S. A.; Niioka, T.; Sawada, K. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation J. Hematol. Oncol. 2012, 5, 23
39. Blobaum, A. L.; Marnett, L. J. Structural and functional basis of cyclooxygenase inhibition J. Med. Chem. 2007, 50, 1425-1441
40. Pairet, M.; Engelhardt, G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications Fundam. Clin. Pharmacol. 1996, 10, 1-17
41. Painful lessons. Nat. Rev. Drug Discovery 2005, 4, 800-803.
42. DrugBank, Open Data Drug & Drug Target Database: Ciclopirox. http://www.drugbank.ca/drugs/DB01188.
43. Bosetti, F.; Weerasinghe, G. R.; Rosenberger, T. A.; Rapoport, S. I. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain J. Neurochem. 2003, 85, 690-696
44. Jannesson, L.; Birkhed, D.; Scherl, D.; Gaffar, A.; Renvert, S. Effect of oxybenzone on PGE2-production in vitro and on plaque and gingivitis in vivo J. Clin. Periodontol. 2004, 31, 91-94
45. Ren, J.; Chung, S. H. Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways J. Agric. Food Chem. 2007, 55, 5073-5080
46. Ren, J.; Han, E. J.; Chung, S. H. In vivo and in vitro anti-inflammatory activities of alpha-linolenic acid isolated from Actinidia polygama fruits Arch. Pharm. Res. 2007, 30, 708-714
47. Naveh, N.; Weissman, C.; Dottan, S. A. Azathioprine's inhibitory effect on prostaglandin E2 production is not via cyclooxygenase inhibition Biochem. Biophys. Res. Commun. 1988, 157, 727-732
48. Sharis, P. J.; Cannon, C. P.; Loscalzo, J. The antiplatelet effects of ticlopidine and clopidogrel Ann. Intern. Med. 1998, 129, 394-405
49. Richer, C.; Giroux, B.; Plouin, P. F.; Maarek, B.; Giudicelli, J. F. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients Br. J. Clin. Pharmacol. 1984, 17, 243-250
50. Jiang, H.; Taggart, J. E.; Zhang, X.; Benbrook, D. M.; Lind, S. E.; Ding, W. Q. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline) Cancer Lett. 2011, 312, 11-17
51. Sosic, I.; Mirkovic, B.; Arenz, K.; Stefane, B.; Kos, J.; Gobec, S. Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives J. Med. Chem. 2013, 56, 521-533
52. Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia Clin. Schizophr. Relat. Psychoses 2010, 4, 56-73
53. Kaizaki, A.; Tien, L. T.; Pang, Y.; Cai, Z.; Tanaka, S.; Numazawa, S.; Bhatt, A. J.; Fan, L. W. Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide J Neuroinflammation 2013, 10, 45
54. Akhondzadeh, S.; Jafari, S.; Raisi, F.; Nasehi, A. A.; Ghoreishi, A.; Salehi, B.; Mohebbi-Rasa, S.; Raznahan, M.; Kamalipour, A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial Depression Anxiety 2009, 26, 607-611
55. Akhondzadeh, S.; Tabatabaee, M.; Amini, H.; Abhari, S. A. A.; Abbasi, S. H.; Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial Schizophr. Res. 2007, 90, 179
56. Gattaz, W. F.; Abrahao, A. L.; Foccacia, R. Childhood meningitis, brain maturation and the risk of psychosis Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254, 23-26
57. Muller, N.; Krause, D.; Dehning, S.; Musil, R.; Schennach-Wolff, R.; Obermeier, M.; Moller, H. J.; Klauss, V.; Schwarz, M. J.; Riedel, M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment Schizophr. Res. 2010, 121, 118-124
58. Muller, N.; Schwarz, M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission Neurotoxic Res. 2006, 10, 131-148
59. Potvin, S.; Stip, E.; Sepehry, A. A.; Gendron, A.; Bah, R.; Kouassi, E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review Biol. Psychiatry 2008, 63, 801-808
60. Akhondzadeh, S.; Tabatabaee, M.; Amini, H.; Ahmadi Abhari, S. A.; Abbasi, S. H.; Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial Schizophr. Res. 2007, 90, 179-185
61. Muller, N.; Riedel, M.; Scheppach, C.; Brandstatter, B.; Sokullu, S.; Krampe, K.; Ulmschneider, M.; Engel, R. R.; Moller, H. J.; Schwarz, M. J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia Am. J. Psychiatry 2002, 159, 1029-1034
62. Muller, N.; Schwarz, M. J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Muller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; Moller, H. J.; Arolt, V.; Riedel, M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Mol. Psychiatry 2006, 11, 680-684
63. Brumbaugh, M.; Price, P.; Fagan, N.; Hsieh, H. Psychotic mania associated with mefloquine in a bipolar patient South. Med. J. 2008, 101, 550-551
64. Tran, T. M.; Browning, J.; Dell, M. L. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report Malar. J. 2006, 5, 74
65. Alisky, J. M.; Chertkova, E. L.; Iczkowski, K. A. Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis Med. Hypotheses 2006, 67, 1090-1094
66. Akhondzadeh, S.; Nejatisafa, A. A.; Amini, H.; Mohammadi, M. R.; Larijani, B.; Kashani, L.; Raisi, F.; Kamalipour, A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27, 1007-1012
67. Kulkarni, J.; de Castella, A.; Fitzgerald, P. B.; Gurvich, C. T.; Bailey, M.; Bartholomeusz, C.; Burger, H. Estrogen in severe mental illness: a potential new treatment approach Arch. Gen. Psychiatry 2008, 65, 955-960
68. Kulkarni, J.; de Castella, A.; Headey, B.; Marston, N.; Sinclair, K.; Lee, S.; Gurvich, C.; Fitzgerald, P. B.; Burger, H. Estrogens and men with schizophrenia: Is there a case for adjunctive therapy? Schizophr. Res. 2011, 125, 278-283
69. Kulkarni, J.; deCastella, A.; Smith, D.; Taffe, J.; Keks, N.; Copolov, D. A clinical trial of the effects of estrogen in acutely psychotic women Schizophr. Res. 1996, 20, 247
70. Kulkarni, J.; Gurvich, C.; Lee, S. J.; Gilbert, H.; Gavrilidis, E.; de, C. A.; Berk, M.; Dodd, S.; Fitzgerald, P. B.; Davis, S. R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia Psychoneuroendocrinology 2010, 35, 1142
71. Usall, J.; Huerta-Ramos, E.; Iniesta, R.; Cobo, J.; Araya, S.; Roca, M.; Serrano-Blanco, A.; Teba, F.; Ochoa, S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial J. Clin. Psychiatry 2011, 72, 1552-1557
72. Muramatsu, H.; Sawanishi, H.; Iwasaki, N.; Kakiuchi, M.; Ohashi, T.; Kato, H.; Ito, Y. Study on zwitter-ionization of drugs. II. Synthesis and pharmacological activity of some N -[3-(5 H -dibenzo[ a, d ]cyclohepten-5- ylidene)propyl]- N -methylamino- and N -[3-(6 H -dibenz[ b, e ]oxepin-11-ylidene)propyl]- N -methylamino-alkanoic acid derivatives and related compounds Chem. Pharm. Bull. (Tokyo) 1993, 41, 1987-1993
73. Stevenson, P. A.; Dyakonova, V.; Rillich, J.; Schildberger, K. Octopamine and experience-dependent modulation of aggression in crickets J. Neurosci. 2005, 25, 1431-1441
74. Roeder, T.; Degen, J.; Gewecke, M. Epinastine, a highly specific antagonist of insect neuronal octopamine receptors Eur. J. Pharmacol. 1998, 349, 171-177
75. Unoki, S.; Matsumoto, Y.; Mizunami, M. Participation of octopaminergic reward system and dopaminergic punishment system in insect olfactory learning revealed by pharmacological study Eur. J. Neurosci. 2005, 22, 1409-1416
76. Unoki, S.; Matsumoto, Y.; Mizunami, M. Roles of octopaminergic and dopaminergic neurons in mediating reward and punishment signals in insect visual learning Eur. J. Neurosci. 2006, 24, 2031-2038
77. Yokoyama, H.; Yano, R.; Aoki, E.; Kato, H.; Araki, T. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice Metab. Brain Dis. 2008, 23, 335-349
78. Brown, E. E.; Nomikos, G. G.; Wilson, C.; Fibiger, H. C. Chronic desipramine enhances the effect of locally applied amphetamine on interstitial concentrations of dopamine in the nucleus accumbens Eur. J. Pharmacol. 1991, 202, 125-127
79. Nomikos, G. G.; Damsma, G.; Wenkstern, D.; Fibiger, H. C. Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens Eur. J. Pharmacol. 1991, 195, 63-73
80. Smialowski, A. Dopamine D2 receptor blocking effect of imipramine in the rat hippocampus Pharmacol., Biochem. Behav. 1991, 39, 105-108
81. Tadokoro, S.; Okamura, N.; Sekine, Y.; Kanahara, N.; Hashimoto, K.; Iyo, M. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis Schizophr Bull. 2012, 38, 1012-1020
82. Golembiewski, J. A.; O'Brien, D. A systematic approach to the management of postoperative nausea and vomiting J. Perianesth. Nurs. 2002, 17, 364-376
83. Oka, M.; Kimura, Y.; Itoh, Y.; Sasaki, Y.; Taniguchi, N.; Ukai, Y.; Yoshikuni, Y.; Kimura, K. Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats Brain Res. 1996, 727, 91-98
84. Simon, Z.; Vigh-Smeller, M.; Peragovics, A.; Csukly, G.; Zahoranszky-Kohalmi, G.; Rauscher, A. A.; Jelinek, B.; Hari, P.; Bitter, I.; Malnasi-Csizmadia, A; Czobor, P. Relating the shape of protein binding sites to binding affinity profiles: Is there an association? BMC Struct. Biol. 2010, 10, 32
85. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets Nucleic Acids Res. 2008, 36, D901-D906
86. Jiang, X.; Kumar, K.; Hu, X.; Wallqvist, A.; Reifman, J. DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0 Chem. Cent. J. 2008, 2, 18
87. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation J. Comput. Chem. 2007, 28, 1145-1152
88. Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction J. Comput.-Aided Mol. Des. 2002, 16, 11-26
89. Lam le, H.; Shimamura, T.; Manabe, S.; Ishiyama, M.; Ukeda, H. Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyrate with water-soluble tetrazolium salt Anal. Sci. 2008, 24, 1057-1060
90. Lam le, H.; Shimamura, T.; Sakaguchi, K.; Noguchi, K.; Ishiyama, M.; Fujimura, Y.; Ukeda, H. Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyric acid Anal. Biochem. 2007, 364, 104-111
91. Nurtjahja-Tjendraputra, E.; Ammit, A. J.; Roufogalis, B. D.; Tran, V. H.; Duke, C. C. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger Thromb. Res. 2003, 111, 259-265
92. Zykova, T. A.; Zhu, F.; Zhai, X.; Ma, W. Y.; Ermakova, S. P.; Lee, K. W.; Bode, A. M.; Dong, Z. Resveratrol directly targets COX-2 to inhibit carcinogenesis Mol. Carcinog. 2008, 47, 797-805